Contact US

Dr Griffiths’ career started out in academia and gave him many years postdoctoral experience. Subsequently, he took a challenging role in industry in the field of Systems Biology. Working in this field led him to specialise in High Content Analysis, which is highly compatible with generating the very rich data sets required for Systems Biology. Promotion to a position central to the High Content Screening facility within AstraZeneca provided him with a deep understanding of its usage and benefits across a large number of diverse projects. He gained hands on experience in a whole array of algorithms for analysing images and now has expert knowledge in this area. His desire was to form his own company based around these skills and so he left AstraZeneca to become Chief Scientific Officer and co-founder of Imagen Therapeutics (formerly Imagen Biotech). Since working for Imagen Therapeutics, Gareth has developed many new and exciting phenotypic screening assays, including a detailed morphology assay that can successfully cluster chemotherapeutic compounds. Gareth is also the creator of the main assay we now use to measure the cell death response of primary patient samples. This assay is not antibody-based, meaning that it can be conducted in both 2D and 3D culture modes.

Privacy Settings
We use cookies to enhance your experience while using our website. If you are using our Services via a browser you can restrict, block or remove cookies through your web browser settings. We also use content and scripts from third parties that may use tracking technologies. You can selectively provide your consent below to allow such third party embeds. For complete information about the cookies we use, data we collect and how we process them, please check our Privacy Policy
Consent to display content from Youtube
Consent to display content from Vimeo
Google Maps
Consent to display content from Google
Consent to display content from Spotify
Sound Cloud
Consent to display content from Sound
Contact Us

© Copyright 2022 Imagen Therapeutics Ltd